샘플 요청 목록

 카트 문의
시장보고서
상품코드
1449254

구강 점막 치료제 시장 : 점유율, 규모, 동향 및 산업 분석 보고서 - 제품 유형별, 투여 경로별, 적응증별, 유통 채널별, 지역별, 부문별 예측(2024-2032년)

Oral Transmucosal Drugs Market Share, Size, Trends, Industry Analysis Report, By Product Type (Tablets, Films), By Route of Administration, By Indication, By Distribution Channel, By Region, And Segment Forecasts, 2024 - 2032
발행일: | 리서치사: Polaris Market Research | 페이지 정보: 영문 115 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

구강 점막 치료제 세계 시장 규모는 2032년까지 829억 9,000만 달러에 달할 것으로 예상됩니다. 이 보고서는 현재 시장 역학에 대한 자세한 통찰력과 미래 시장 성장에 대한 분석을 제공합니다.

연구 개발 노력의 급증은 신제품 출시와 대상 질환의 유병률 증가와 함께 시장 성장을 가속할 태세를 갖추고 있습니다. 또한, 대상 인구 증가는 시장 확대에 기여할 것으로 예상됩니다. 경구용 펜타닐 구연산염의 독특한 제형인 구강점막용 펜타닐 구연산염은 펜타닐을 로젠지에 통합하여 구강 내 점막을 통해 약물을 전달하여 1차 통과 대사를 우회함으로써 경구 경로에 비해 생체이용률을 향상시킵니다.

그 결과, 다양한 장애로 인한 즉각적인 통증 완화를 원하는 환자 집단에서 오피오이드 의존도가 높아지면서 경구용 경점막 약물에 대한 수요가 증가할 가능성이 높습니다. 예를 들어, 2021년 세계보건기구(WHO) 데이터에 따르면 전 세계적으로 약 2억 7,500만 명이 약물을 사용하고 있으며, 그 중 약 6,200만 명이 오피오이드를 사용하고 있습니다.

파킨슨병(PD)과 편두통의 유병률 증가는 시장 확대의 원동력이 될 것으로 예상됩니다. 예를 들어, 2022년 1월에 발표된 Parkinson's Foundation의 자료에 따르면, 현재 미국에서 약 1,000만 명이 파킨슨병을 앓고 있으며, 2030년에는 약 1,200만 명으로 증가할 것으로 예상됩니다. 파킨슨병은 알츠하이머병에 이어 두 번째로 흔한 신경 퇴행성 질환으로, 매년 6만 명 이상의 미국인이 파킨슨병 진단을 받고 있습니다. 이러한 질병 유병률 증가는 통증 관리 개선과 즉각적인 완화를 위해 경구용 경점막 치료제의 채택을 촉진할 것으로 보입니다.

2021년 1월 현재, CDC 데이터에 따르면 미국 65세 이상 성인의 26%가 8개 이하의 치아를 가지고 있으며, 같은 연령대의 성인 6명 중 1명(17%)이 모든 치아를 잃은 것으로 나타났습니다. 또한, 2022년 2월 CDC 데이터에 따르면, 미국 18세 이상 성인의 63%가 지난 1년간 치과를 방문했으며, 2-17세 아동의 85.9%가 2020년에 치과를 방문한 것으로 나타났습니다. 이러한 치과 방문 증가는 미다졸람, 부프레노르핀과 같은 진정 및 진통용 경구용 경점막 약물에 대한 수요를 촉진할 것으로 예상됩니다.

구강 점막 치료제 시장 보고서 하이라이트

사용의 편리성, 흡수성, 효율성이 높은 정제가 가장 큰 점유율을 차지

오피오이드 중독이 시장을 휩쓸고 있는데, 이는 주로 오피오이드 장애 증가에 기인합니다.

설하제는 급성통증 시 선호도가 높아 가장 큰 점유율을 차지

APAC은 스트레스와 정신 질환을 앓고 있는 인구가 많기 때문에 가장 빠른 속도로 성장할 것으로 예상됩니다.

시장 진출기업으로는 Aquestive Therapeutics, C.L. Pharm, GW Pharmaceuticals, IntelGenx, Pfizer, Seoul Pharmaceuticals, Shilpa Therapeutics 등이 있습니다.

목차

제1장 서론

제2장 주요 요약

제3장 조사 방법

제4장 세계의 구강 점막 치료제 시장 인사이트

  • 구강 점막 치료제 - 업계 현황
  • 구강 점막 치료제 시장 역학
    • 성장 촉진요인과 기회
    • 성장 억제요인과 과제
  • PESTLE 분석
  • 구강 점막 치료제 업계 동향
  • 밸류체인 분석
  • COVID-19의 영향 분석

제5장 세계의 경구 점막약시장 : 제품 유형별

  • 주요 조사 결과
  • 서론
  • 정제
  • 필름
  • 액체 및 스프레이
  • 기타

제6장 세계의 구강 점막 치료제 시장 : 투여 경로별

  • 주요 조사 결과
  • 서론
  • 설하 점막
  • 기타

제7장 세계의 구강 점막 치료제 시장 : 적응증별

  • 주요 조사 결과
  • 서론
  • 오피오이드 의존증
  • 메스꺼움 및 구토
  • 발기부전
  • 신경 장애
  • 기타

제8장 세계의 구강 점막 치료제 시장 : 유통 채널별

  • 주요 조사 결과
  • 서론
  • 병원 약국
  • 소매 약국
  • 온라인 약국

제9장 세계의 구강 점막 치료제 시장 : 지역별

  • 주요 조사 결과
  • 서론
    • 구강 점막 치료제 시장 평가 : 지역별(2019년-2032년)
  • 구강 점막 치료제 시장 - 북미
    • 제품 유형별(2019년-2032년)
    • 유통 채널별(2019년-2032년)
    • 투여 경로별(2019년-2032년)
    • 적응증별(2019년-2032년)
    • 미국
    • 캐나다
  • 구강 점막 치료제 시장 - 유럽
    • 제품 유형별(2019년-2032년)
    • 유통 채널별(2019년-2032년)
    • 투여 경로별(2019년-2032년)
    • 적응증별(2019년-2032년)
    • 영국
    • 프랑스
    • 독일
    • 이탈리아
    • 스페인
    • 네덜란드
    • 러시아
  • 구강 점막 치료제 시장 - 아시아태평양
    • 제품 유형별(2019년-2032년)
    • 유통 채널별(2019년-2032년)
    • 투여 경로별(2019년-2032년)
    • 적응증별(2019년-2032년)
    • 중국
    • 인도
    • 일본
    • 말레이시아
    • 인도네시아
    • 한국
  • 구강 점막 치료제 시장 - 중동 및 아프리카
    • 제품 유형별(2019년-2032년)
    • 유통 채널별(2019년-2032년)
    • 투여 경로별(2019년-2032년)
    • 적응증별(2019년-2032년)
    • 사우디아라비아
    • 남아프리카공화국
    • 이스라엘
    • 아랍에미리트(UAE)
  • 구강 점막 치료제 시장 - 라틴아메리카
    • 제품 유형별(2019년-2032년)
    • 유통 채널별(2019년-2032년)
    • 투여 경로별(2019년-2032년)
    • 적응증별(2019년-2032년)
    • 멕시코
    • 브라질
    • 아르헨티나

제10장 경쟁 구도

  • 확장 및 인수 분석
    • 확장
    • 인수
  • 제휴/협업/합의/공개

제11장 기업 개요

  • Aquestive Therapeutics, Inc
  • C.L.Pharm Co., Ltd
  • GW Pharmaceuticals plc
  • IntelGenx Corp
  • IntelGenx Corp
  • Pfizer Inc
  • Seoul Pharmaceuticals
  • Shilpa Therapeutics
  • Sunovion Pharmaceuticals, Inc.
  • ZIM Laboratories Limited
LSH 24.03.26

The global oral transmucosal drugs market size is expected to reach USD 82.99 billion by 2032, according to a new study by Polaris Market Research. The report "Oral Transmucosal Drugs Market Share, Size, Trends, Industry Analysis Report, By Product Type (Tablets, Films), By Route of Administration, By Indication, By Distribution Channel, By Region, And Segment Forecasts, 2024 - 2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.

The surge in research and development endeavors, coupled with new product launches and an increase in the prevalence of targeted diseases, is poised to propel market growth. Additionally, the growth in the target population is expected to contribute to the market's expansion. The unique formulation of oral transmucosal fentanyl citrate, incorporating fentanyl in a lozenge for drug delivery through the buccal mucosa, offers enhanced bioavailability compared to the oral route by bypassing first-pass metabolism.

Consequently, the growing opioid dependence within the patient population seeking immediate relief from pain associated with various disorders is likely to drive the demand for oral transmucosal drugs, for example, as per the World Health Organization's data from 2021, around 275 million people globally used medications, with approximately 62 million among them using opioids.

The growing prevalence of Parkinson's disease (PD) and migraine is anticipated to drive the expansion of the market. For instance, data from the Parkinson's Foundation, January 2022, reveals that nearly one million people in the United States are currently living with Parkinson's disease, with projections indicating an increase to around 1.2 Mn by 2030. Parkinson's disease stands as the second-most common neurodegenerative disease, following Alzheimer's disease, with over 60,000 Americans diagnosed annually and a global population exceeding 10 Mn individuals living with PD. The rising incidences of such disorders are likely to boost the adoption of oral transmucosal drugs for their treatment, leading to improved pain management and immediate relief.

As of January 2021, data from the CDC indicates that 26% of adults aged 65 or older had eight or fewer teeth, and approximately 1 in 6 (17%) adults in the same age group had lost all their teeth in the United States. Additionally, according to CDC data from February 2022, 63% of adults aged 18 and over in the United States had a dental visit in the past year, and 85.9% of children aged 2-17 years had a dental visit in the year 2020. This rise in dental visits is expected to fuel the demand for oral transmucosal drugs, such as midazolam and buprenorphine, for sedation and pain relief.

Oral Transmucosal Drugs Market Report Highlights

Tablets segment held the largest share, owing to its ease of use, easy absorption, and have higher efficiency

Opioid dependence segment dominated the market, primarily due to rising cases of opioid disorders

Sub-lingual drugs garnered the largest share, as they are mostly preferred during acute pain conditions

APAC expected to grow at the fastest rate, due to presence of huge population suffering with stress and mental conditions

The market players include Aquestive Therapeutics, C.L. Pharm, GW Pharmaceuticals, IntelGenx, Pfizer, Seoul Pharmaceuticals, and Shilpa Therapeutics

Polaris Market Research has segmented the oral transmucosal drugs market report based on product type, route of administration, indication, distribution channel, and region:

Oral Transmucosal Drugs, Product Type Outlook (Revenue - USD Billion, 2019 - 2032)

  • Tablets
  • Films
  • Liquid & Spray
  • Others

Oral Transmucosal Drugs, Route of Administration Outlook (Revenue - USD Billion, 2019 - 2032)

  • Sublingual Mucosa
  • Buccal Mucosa
  • Others

Oral Transmucosal Drugs, Indication Outlook (Revenue - USD Billion, 2019 - 2032)

  • Opioid Dependence
  • Nausea and Vomiting
  • Erectile Dysfunction
  • Neurological Disorders
  • Others

Oral Transmucosal Drugs, Distribution Channel Outlook (Revenue - USD Billion, 2019 - 2032)

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Oral Transmucosal Drugs, Regional Outlook (Revenue - USD Billion, 2019 - 2032)

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Netherlands
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Malaysia
  • Latin America
  • Argentina
  • Brazil
  • Mexico
  • Middle East & Africa
  • UAE
  • Saudi Arabia
  • Israel
  • South Africa

Table of Contents

1.Introduction

  • 1.1.Report Description
    • 1.1.1.Objectives of the Study
    • 1.1.2.Market Scope
    • 1.1.3.Assumptions
  • 1.2.Stakeholders

2.Executive Summary

  • 2.1.Market Highlights

3.Research Methodology

  • 3.1.Overview
    • 3.1.1.Data Mining
  • 3.2.Data Sources
    • 3.2.1.Primary Sources
    • 3.2.2.Secondary Sources

4.Global Oral Transmucosal Drugs Market Insights

  • 4.1.Oral Transmucosal Drugs - Industry Snapshot
  • 4.2.Oral Transmucosal Drugs Market Dynamics
    • 4.2.1.Drivers and Opportunities
      • 4.2.1.1.Increasing use of Oral Transmucosal Drugs technology in healthcare
      • 4.2.1.2.Technological advancement
    • 4.2.2.Restraints and Challenges
      • 4.2.2.1.Increasing digitization will restrict the market growth
  • 4.3.Porter's Five Forces Analysis
    • 4.3.1.Bargaining Power of Suppliers (Moderate)
    • 4.3.2.Threats of New Entrants: (Low)
    • 4.3.3.Bargaining Power of Buyers (Moderate)
    • 4.3.4.Threat of Substitute (Moderate)
    • 4.3.5.Rivalry among existing firms (High)
  • 4.4.PESTLE Analysis
  • 4.5.Oral Transmucosal Drugs Industry Trends
  • 4.6.Value Chain Analysis
  • 4.7.COVID-19 Impact Analysis

5.Global Oral Transmucosal Drugs Market, by Product Distribution Channel

  • 5.1.Key Findings
  • 5.2.Introduction
    • 5.2.1.Global Oral Transmucosal Drugs Market, by Product Distribution Channel, 2019-2032 (USD Billion)
  • 5.3.Tablets
    • 5.3.1.Global Oral Transmucosal Drugs Market, by Tablets, by Region, 2019-2032 (USD Billion)
  • 5.4.Films
    • 5.4.1.Global Oral Transmucosal Drugs Market, by Films, by Region, 2019-2032 (USD Billion)
  • 5.5.Liquid & Spray
    • 5.5.1.Global Oral Transmucosal Drugs Market, by Liquid & Spray, by Region, 2019-2032 (USD Billion)
  • 5.6.Others
    • 5.6.1.Global Oral Transmucosal Drugs Market, by Others , by Region, 2019-2032 (USD Billion)

6.Global Oral Transmucosal Drugs Market, by Route of Administration

  • 6.1.Key Findings
  • 6.2.Introduction
    • 6.2.1.Global Oral Transmucosal Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
  • 6.3.Sublingual Mucosa
    • 6.3.1.Global Oral Transmucosal Drugs Market, by Sublingual Mucosa, by Region, 2019-2032 (USD Billion)
  • 6.4.Sublingual Mucosa
    • 6.4.1.Global Oral Transmucosal Drugs Market, by Sublingual Mucosa, by Region, 2019-2032 (USD Billion)
  • 6.5.Others
    • 6.5.1.Global Oral Transmucosal Drugs Market, by Others, by Region, 2019-2032 (USD Billion)

7.Global Oral Transmucosal Drugs Market, by Indication

  • 7.1.Key Findings
  • 7.2.Introduction
    • 7.2.1.Global Oral Transmucosal Drugs Market, by Indication, 2019-2032 (USD Billion)
  • 7.3.Opioid Dependence
    • 7.3.1.Global Oral Transmucosal Drugs Market, by Opioid Dependence, by Region, 2019-2032 (USD Billion)
  • 7.4.Nausea and Vomiting
    • 7.4.1.Global Oral Transmucosal Drugs Market, by Nausea and Vomiting, by Region, 2019-2032 (USD Billion)
  • 7.5.Erectile Dysfunction
    • 7.5.1.Global Oral Transmucosal Drugs Market, by Erectile Dysfunction, by Region, 2019-2032 (USD Billion)
  • 7.6.Neurological Disorders
    • 7.6.1.Global Oral Transmucosal Drugs Market, by Neurological Disorders, by Region, 2019-2032 (USD Billion)
  • 7.7.Others
    • 7.7.1.Global Oral Transmucosal Drugs Market, by Others, by Region, 2019-2032 (USD Billion)

8.Global Oral Transmucosal Drugs Market, by Distribution Channel

  • 8.1.Key Findings
  • 8.2.Introduction
    • 8.2.1.Global Oral Transmucosal Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
  • 8.3.Hospital Pharmacies
    • 8.3.1.Global Oral Transmucosal Drugs Market, by Hospital Pharmacies, by Region, 2019-2032 (USD Billion)
  • 8.4.Retail Pharmacies
    • 8.4.1.Global Oral Transmucosal Drugs Market, by Retail Pharmacies, by Region, 2019-2032 (USD Billion)
  • 8.5.Online Pharmacies
    • 8.5.1.Global Oral Transmucosal Drugs Market, by Online Pharmacies, by Region, 2019-2032 (USD Billion)

9.Global Oral Transmucosal Drugs Market, by Geography

  • 9.1.Key findings
  • 9.2.Introduction
    • 9.2.1.Oral Transmucosal Drugs Market Assessment, By Geography, 2019-2032 (USD Billion)
  • 9.3.Oral Transmucosal Drugs Market - North America
    • 9.3.1.North America: Oral Transmucosal Drugs Market, by Product Distribution Channel, 2019-2032 (USD Billion)
    • 9.3.2.North America: Oral Transmucosal Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
    • 9.3.3.North America: Oral Transmucosal Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
    • 9.3.4.North America: Oral Transmucosal Drugs Market, by Indication, 2019-2032 (USD Billion)
    • 9.3.5.Oral Transmucosal Drugs Market - U.S.
      • 9.3.5.1.U.S.: Oral Transmucosal Drugs Market, by Product Distribution Channel, 2019-2032 (USD Billion)
      • 9.3.5.2.U.S.: Oral Transmucosal Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 9.3.5.3.U.S.: Oral Transmucosal Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
      • 9.3.5.4.U.S.: Oral Transmucosal Drugs Market, by Indication, 2019-2032 (USD Billion)
    • 9.3.6.Oral Transmucosal Drugs Market - Canada
      • 9.3.6.1.Canada: Oral Transmucosal Drugs Market, by Product Distribution Channel, 2019-2032 (USD Billion)
      • 9.3.6.2.Canada: Oral Transmucosal Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 9.3.6.3.Canada: Oral Transmucosal Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
      • 9.3.6.4.Canada: Oral Transmucosal Drugs Market, by Indication, 2019-2032 (USD Billion)
  • 9.4.Oral Transmucosal Drugs Market - Europe
    • 9.4.1.Europe: Oral Transmucosal Drugs Market, by Product Distribution Channel, 2019-2032 (USD Billion)
    • 9.4.2.Europe: Oral Transmucosal Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
    • 9.4.3.Europe: Oral Transmucosal Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
    • 9.4.4.Europe: Oral Transmucosal Drugs Market, by Indication, 2019-2032 (USD Billion)
    • 9.4.5.Oral Transmucosal Drugs Market - UK
      • 9.4.5.1.UK: Oral Transmucosal Drugs Market, by Product Distribution Channel, 2019-2032 (USD Billion)
      • 9.4.5.2.UK: Oral Transmucosal Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 9.4.5.3.UK: Oral Transmucosal Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
      • 9.4.5.4.UK: Oral Transmucosal Drugs Market, by Indication, 2019-2032 (USD Billion)
    • 9.4.6.Oral Transmucosal Drugs Market - France
      • 9.4.6.1.France: Oral Transmucosal Drugs Market, by Product Distribution Channel, 2019-2032 (USD Billion)
      • 9.4.6.2.France: Oral Transmucosal Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 9.4.6.3.France: Oral Transmucosal Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
      • 9.4.6.4.France: Oral Transmucosal Drugs Market, by Indication, 2019-2032 (USD Billion)
    • 9.4.7.Oral Transmucosal Drugs Market - Germany
      • 9.4.7.1.Germany: Oral Transmucosal Drugs Market, by Product Distribution Channel, 2019-2032 (USD Billion)
      • 9.4.7.2.Germany: Oral Transmucosal Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 9.4.7.3.Germany: Oral Transmucosal Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
      • 9.4.7.4.Germany: Oral Transmucosal Drugs Market, by Indication, 2019-2032 (USD Billion)
    • 9.4.8.Oral Transmucosal Drugs Market - Italy
      • 9.4.8.1.Italy: Oral Transmucosal Drugs Market, by Product Distribution Channel, 2019-2032 (USD Billion)
      • 9.4.8.2.Italy: Oral Transmucosal Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 9.4.8.3.Italy: Oral Transmucosal Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
      • 9.4.8.4.Italy: Oral Transmucosal Drugs Market, by Indication, 2019-2032 (USD Billion)
    • 9.4.9.Oral Transmucosal Drugs Market - Spain
      • 9.4.9.1.Spain: Oral Transmucosal Drugs Market, by Product Distribution Channel, 2019-2032 (USD Billion)
      • 9.4.9.2.Spain: Oral Transmucosal Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 9.4.9.3.Spain: Oral Transmucosal Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
      • 9.4.9.4.Spain: Oral Transmucosal Drugs Market, by Indication, 2019-2032 (USD Billion)
    • 9.4.10.Oral Transmucosal Drugs Market - Netherlands
      • 9.4.10.1.Netherlands: Oral Transmucosal Drugs Market, by Product Distribution Channel, 2019-2032 (USD Billion)
      • 9.4.10.2.Netherlands: Oral Transmucosal Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 9.4.10.3.Netherlands: Oral Transmucosal Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
      • 9.4.10.4.Netherlands: Oral Transmucosal Drugs Market, by Indication, 2019-2032 (USD Billion)
    • 9.4.11.Oral Transmucosal Drugs Market - Russia
      • 9.4.11.1.Russia: Oral Transmucosal Drugs Market, by Product Distribution Channel, 2019-2032 (USD Billion)
      • 9.4.11.2.Russia.: Oral Transmucosal Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 9.4.11.3.Russia: Oral Transmucosal Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
      • 9.4.11.4.Russia: Oral Transmucosal Drugs Market, by Indication, 2019-2032 (USD Billion)
  • 9.5.Oral Transmucosal Drugs Market - Asia Pacific
    • 9.5.1.Asia Pacific: Oral Transmucosal Drugs Market, by Product Distribution Channel, 2019-2032 (USD Billion)
    • 9.5.2.Asia Pacific: Oral Transmucosal Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
    • 9.5.3.Asia Pacific: Oral Transmucosal Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
    • 9.5.4.Asia Pacific: Oral Transmucosal Drugs Market, by Indication, 2019-2032 (USD Billion)
    • 9.5.5.Oral Transmucosal Drugs Market - China
      • 9.5.5.1.China: Oral Transmucosal Drugs Market, by Product Distribution Channel, 2019-2032 (USD Billion)
      • 9.5.5.2.China.: Oral Transmucosal Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 9.5.5.3.China: Oral Transmucosal Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
      • 9.5.5.4.China: Oral Transmucosal Drugs Market, by Indication, 2019-2032 (USD Billion)
    • 9.5.6.Oral Transmucosal Drugs Market - India
      • 9.5.6.1.India: Oral Transmucosal Drugs Market, by Product Distribution Channel, 2019-2032 (USD Billion)
      • 9.5.6.2.India.: Oral Transmucosal Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 9.5.6.3.India: Oral Transmucosal Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
      • 9.5.6.4.India: Oral Transmucosal Drugs Market, by Indication, 2019-2032 (USD Billion)
    • 9.5.7.Oral Transmucosal Drugs Market - Japan
      • 9.5.7.1.Japan: Oral Transmucosal Drugs Market, by Product Distribution Channel, 2019-2032 (USD Billion)
      • 9.5.7.2.Japan.: Oral Transmucosal Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 9.5.7.3.Japan: Oral Transmucosal Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
      • 9.5.7.4.Japan: Oral Transmucosal Drugs Market, by Indication, 2019-2032 (USD Billion)
    • 9.5.8.Oral Transmucosal Drugs Market - Malaysia
      • 9.5.8.1.Malaysia: Oral Transmucosal Drugs Market, by Product Distribution Channel, 2019-2032 (USD Billion)
      • 9.5.8.2.Malaysia.: Oral Transmucosal Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 9.5.8.3.Malaysia: Oral Transmucosal Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
      • 9.5.8.4.Malaysia: Oral Transmucosal Drugs Market, by Indication, 2019-2032 (USD Billion)
    • 9.5.9.Oral Transmucosal Drugs Market - Indonesia
      • 9.5.9.1.Indonesia: Oral Transmucosal Drugs Market, by Product Distribution Channel, 2019-2032 (USD Billion)
      • 9.5.9.2.Indonesia.: Oral Transmucosal Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 9.5.9.3.Indonesia: Oral Transmucosal Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
      • 9.5.9.4.Indonesia: Oral Transmucosal Drugs Market, by Indication, 2019-2032 (USD Billion)
    • 9.5.10.Oral Transmucosal Drugs Market - South Korea
      • 9.5.10.1.South Korea: Oral Transmucosal Drugs Market, by Product Distribution Channel, 2019-2032 (USD Billion)
      • 9.5.10.2.South Korea.: Oral Transmucosal Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 9.5.10.3.South Korea: Oral Transmucosal Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
      • 9.5.10.4.South Korea: Oral Transmucosal Drugs Market, by Indication, 2019-2032 (USD Billion)
  • 9.6.Oral Transmucosal Drugs Market - Middle East & Africa
    • 9.6.1.Middle East & Africa: Oral Transmucosal Drugs Market, by Product Distribution Channel, 2019-2032 (USD Billion)
    • 9.6.2.Middle East & Africa: Oral Transmucosal Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
    • 9.6.3.Middle East & Africa: Oral Transmucosal Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
    • 9.6.4.Middle East & Africa: Oral Transmucosal Drugs Market, by Indication, 2019-2032 (USD Billion)
    • 9.6.5.Oral Transmucosal Drugs Market - Saudi Arabia
      • 9.6.5.1.Saudi Arabia: Oral Transmucosal Drugs Market, by Product Distribution Channel, 2019-2032 (USD Billion)
      • 9.6.5.2.Saudi Arabia: Oral Transmucosal Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 9.6.5.3.Saudi Arabia: Oral Transmucosal Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
      • 9.6.5.4.Saudi Arabia: Oral Transmucosal Drugs Market, by Indication, 2019-2032 (USD Billion)
    • 9.6.6.Oral Transmucosal Drugs Market - South Africa
      • 9.6.6.1.South Africa: Oral Transmucosal Drugs Market, by Product Distribution Channel, 2019-2032 (USD Billion)
      • 9.6.6.2.South Africa: Oral Transmucosal Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 9.6.6.3.South Africa: Oral Transmucosal Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
      • 9.6.6.4.South Africa: Oral Transmucosal Drugs Market, by Indication, 2019-2032 (USD Billion)
    • 9.6.7.Oral Transmucosal Drugs Market - Israel
      • 9.6.7.1.Israel: Oral Transmucosal Drugs Market, by Product Distribution Channel, 2019-2032 (USD Billion)
      • 9.6.7.2.Israel: Oral Transmucosal Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 9.6.7.3.Israel: Oral Transmucosal Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
      • 9.6.7.4.Israel: Oral Transmucosal Drugs Market, by Indication, 2019-2032 (USD Billion)
    • 9.6.8.Oral Transmucosal Drugs Market - UAE
      • 9.6.8.1.UAE: Oral Transmucosal Drugs Market, by Product Distribution Channel, 2019-2032 (USD Billion)
      • 9.6.8.2.UAE: Oral Transmucosal Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 9.6.8.3.UAE: Oral Transmucosal Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
      • 9.6.8.4.UAE: Oral Transmucosal Drugs Market, by Indication, 2019-2032 (USD Billion)
  • 9.7.Oral Transmucosal Drugs Market - Latin America
    • 9.7.1.Latin America: Oral Transmucosal Drugs Market, by Product Distribution Channel, 2019-2032 (USD Billion)
    • 9.7.2.Latin America: Oral Transmucosal Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
    • 9.7.3.Latin America: Oral Transmucosal Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
    • 9.7.4.Latin America: Oral Transmucosal Drugs Market, by Indication, 2019-2032 (USD Billion)
    • 9.7.5.Oral Transmucosal Drugs Market - Mexico
      • 9.7.5.1.Mexico: Oral Transmucosal Drugs Market, by Product Distribution Channel, 2019-2032 (USD Billion)
      • 9.7.5.2.Mexico: Oral Transmucosal Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 9.7.5.3.Mexico: Oral Transmucosal Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
      • 9.7.5.4.Mexico: Oral Transmucosal Drugs Market, by Indication, 2019-2032 (USD Billion)
    • 9.7.6.Oral Transmucosal Drugs Market - Brazil
      • 9.7.6.1.Brazil: Oral Transmucosal Drugs Market, by Product Distribution Channel, 2019-2032 (USD Billion)
      • 9.7.6.2.Brazil: Oral Transmucosal Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 9.7.6.3.Brazil: Oral Transmucosal Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
      • 9.7.6.4.Brazil: Oral Transmucosal Drugs Market, by Indication, 2019-2032 (USD Billion)
    • 9.7.7.Oral Transmucosal Drugs Market - Argentina
      • 9.7.7.1.Argentina: Oral Transmucosal Drugs Market, by Product Distribution Channel, 2019-2032 (USD Billion)
      • 9.7.7.2.Argentina: Oral Transmucosal Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 9.7.7.3.Argentina: Oral Transmucosal Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
      • 9.7.7.4.Argentina: Oral Transmucosal Drugs Market, by Indication, 2019-2032 (USD Billion)

10.Competitive Landscape

  • 10.1.Expansion and Acquisition Analysis
    • 10.1.1.Expansion
    • 10.1.2.Acquisitions
  • 10.2.Partnerships/Collaborations/Agreements/Exhibitions

11.Company Profiles

  • 11.1.Aquestive Therapeutics, Inc
    • 11.1.1.Company Overview
    • 11.1.2.Financial Performance
    • 11.1.3.Product Benchmarking
    • 11.1.4.Recent Development
  • 11.2.C.L.Pharm Co., Ltd
    • 11.2.1.Company Overview
    • 11.2.2.Financial Performance
    • 11.2.3.Product Benchmarking
    • 11.2.4.Recent Development
  • 11.3.GW Pharmaceuticals plc
    • 11.3.1.Company Overview
    • 11.3.2.Financial Performance
    • 11.3.3.Product Benchmarking
    • 11.3.4.Recent Development
  • 11.4.IntelGenx Corp
    • 11.4.1.Company Overview
    • 11.4.2.Financial Performance
    • 11.4.3.Product Benchmarking
    • 11.4.4.Recent Development
  • 11.5.IntelGenx Corp
    • 11.5.1.Company Overview
    • 11.5.2.Financial Performance
    • 11.5.3.Product Benchmarking
    • 11.5.4.Recent Development
  • 11.6.Pfizer Inc
    • 11.6.1.Company Overview
    • 11.6.2.Financial Performance
    • 11.6.3.Product Benchmarking
    • 11.6.4.Recent Development
  • 11.7.Seoul Pharmaceuticals
    • 11.7.1.Company Overview
    • 11.7.2.Financial Performance
    • 11.7.3.Product Benchmarking
    • 11.7.4.Recent Development
  • 11.8.Shilpa Therapeutics
    • 11.8.1.Company Overview
    • 11.8.2.Financial Performance
    • 11.8.3.Product Benchmarking
    • 11.8.4.Recent Development
  • 11.9.Sunovion Pharmaceuticals, Inc.
    • 11.9.1.Company Overview
    • 11.9.2.Financial Performance
    • 11.9.3.Product Benchmarking
    • 11.9.4.Recent Development
  • 11.10.ZIM Laboratories Limited
    • 11.10.1.Company Overview
    • 11.10.2.Financial Performance
    • 11.10.3.Product Benchmarking
    • 11.10.4.Recent Development
샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제